Fujisawa Pharmaceutical Company, Ltd.

Mineo Niwa

Yoshimasa Saito

Yoshinori Ishii

Ikuo Ueda

Masakazu Kobayashi

Masaru Yoshida

Hitoshi Sasaki

Hiroki Ono

Tadashi Kitaguchi

Hiromi Suzuki

Susumu Sato

Jouji Notani

Masako Hayashi

Hiromi Hayashi

Hirokazu Tanaka

Susumu Satoh

Kouichi Tamura

Hisashi Yamada

Yuji Noguchi

Tsutomu Kaizu

Chihiro Kusunoki

Tadashi Hitaguchi

Kazuyuki Ohtsuka

Takao Fujimura

Yoshimasa Saitoh

DNA fragments which contain a sequence of DNA which encodes a protective peptide-fused &agr;-hANP in which the protective peptide has a C-terminus lysine residue which is directly fused to the N-terminus of the &agr;-hANP, vectors which contain such a DNA sequence, and microorganisms transformed which such a vector are useful for the production of &agr;-hANP.

Process for the production of &agr;-human atrial natriuretic polypeptide

A novel L-sorbose dehydrogenase (SDH) and a novel L-sorbosone dehydrogenase both derived from Gluconobacter oxydans T-100, a DNA which encodes the SDH and/or SNDH, an expression vector which contains the DNA, a host cell transformed by the expression vector and a process for producing the SDH and/or SNDH, which comprises culturing the host cell in a medium and recovering the SDH and/or SNDH from the resulting culture. The SDH and SNDH of the present invention are useful enzymes having preferable properties for the production of 2-keto-L-gulonic acid, as well as L-ascorbic acid. According to the production method of the present invention, the SDH and SNDH having such preferable properties can be produced in large amounts by genetic engineering.

L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase obtained from gluconobacter oxydans T-100

An expression vector containing both a DNA encoding an L-sorbose dehydrogenase and a DNA encoding an L-sorbosone dehydrogenase; a transformant having an ability to produce 2-keto-L-gulonic acid (hereinafter 2KLGA) at high yields from D-sorbitol, which is prepared by transforming, with said expression vector, a microorganism capable of producing L-sorbose at high yields from D-sorbitol, which has no or low 2KLGA-decomposing activity or a host microorganism having, in addition to the above-mentioned properties, no or low L-idonic acid-producing activity; and a process for producing 2KLGA, which comprises culturing said transformant in a medium containing D-sorbitol. According to the present invention, 2KLGA useful for the production of L-ascorbic acid can be produced with ease and in larger amounts by a single operation of culture.

Method for producing 2-keto-L-gulonic acid

A novel L-sorbose dehydrogenase (SDH) and a novel L-sorbosone dehydrogenase (SNDH) both derived from Gluconobacter oxydans T-100, a DNA which encodes the SDH and/or SNDH, an expression vector which contains the DNA, a host cell transformed by the expression vector and a process for producing the SDH and/or SNDH, which comprises culturing the host cell in a medium and recovering the SDH and/or SNDH from the resulting culture. The SDH and SNDH of the present invention are useful enzymes having preferable properties for the production of 2-keto-L-gulonic acid, as well as L-ascorbic acid. According to the production method of the present invention, the SDH and SNDH having such preferable properties can be produced in large amounts by genetic engineering.

L-sorbose dehydrogenase and novel L-sorbosone dehydrogenase obtained

The invention relates to a new tissue plasminogen activator which has strong activity for converting plasminogen into plasmin that degrades the fibrin network of blood clots to form soluble products and therefore is useful as a thrombolytic agent. The invention also relates to a DNA sequence encoding the amino acid sequence for the tissue plasminogen activator, to a process for producing the plasminogen activator, and to a pharmaceutical composition comprising the new tissue plasminogen activator.

Tissue plasminogen activator

Cephalosporin C acylase

Monoclonal antibody recognizing FK506-binding protein, method for

Monoclonal or polyclonal antibodies capable of recognizing at least one antigenic determinant located on the FR-900506 compound, are disclosed. FR-900506 is a compound having pharmacological activities such as immunosuppressive activity and antimicrobial activity, and has the following structure: ##STR1## Also disclosed are enzyme immunoassays for FR-900506 based on the antibodies of the invention and test kits for detection of FR-900506. A process for preparing a monoclonal antibody which selectively binds to FR-900506 is also disclosed.

Anti-FR-900506 substance antibodies and highly-sensitive enzyme

Two-cistronic Met-IGF-I expression vector, in which the first cistron encodes a protective peptide with a molecular weight of about 500-50,000 and the second cistron encodes IGF-I, was provided. Also provided is a process for preparing Met-IGF-I, which comprises transforming E. coli with said vector and growing the resultant transformant, followed by the lysis of the cell culture and isolation of Met-IGF-I.

Expression vector for insulin-like growth factor I and method of

The present invention concerns a mutant cephalosporin C acylase derived from a precursor of the formula:

The cysteine-containing polypeptide is oxidized with hydrogen peroxide to produce the biologically active polypeptide having the intramolecular disulfide bridge.

Process for the formation of intramolecular disulfide bridge in a

IGF-I fused with a protective peptide, in which the protective peptide is a protein peptide and is used for the protection of IGF-I from degradation by protease in cells of E. coli is disclosed. Also disclosed are genes coding for the fused IGF-I's, plasmids containing the genes, and E. coli microorganisms transformed with the plasmids.

Growing community of inventors

Muko, Japan

Mineo Niwa